300009.SZ
安科生物
SZSE · Healthcare · C 制造业 · CN
CNY 8.49
−5.35%Aug 28, 2026, 10:27 UTC
Anke Bio announced it will acquire the remaining 27.4647% equity in Anke Yuliangqing from several shareholders for 54.3238 million yuan, making it a wholly-owned subsidiary.
Source:Aug 25, 2026, 11:17 UTC
Anke Bio announced its first-half 2026 results: revenue of 1.098 billion yuan, down 15.04% year-on-year; net profit attributable to shareholders of 332 million yuan, down 9.33% year-on-year; and no dividend or share transfer plan.
Source:Aug 17, 2026, 11:15 UTC
Anke Bio's marketing authorization application for Cetrorelix Acetate for Injection was accepted by China's National Medical Products Administration.
Source:Jul 10, 2026, 12:04 UTC
Anke Biological and its subsidiaries had 20 products included in the National Essential Drug List (2026 edition), with 3 new additions: trastuzumab injection, tenofovir alafenamide fumarate tablets, and Qingre Jiedu oral liquid.
Source: